Stefanadis C, Synetos A, Tousoulis D, Tsiamis E, Michelongona A, Zagouri F, Bamias A, Dimopoulos MA, Kyvelou S, Kapelakis I, et al. Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer. International Journal of Cardiology [Internet]. 2012;154(3):341 - 344.